Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …

Purpose To compare the effectiveness and safety of reduced or standard daily doses of
direct oral anticoagulants (DOACs) with warfarin in Japanese patients with nonvalvular atrial …

Background Non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred choice
of anticoagulants to prevent stroke in most patients with atrial fibrillation (AF). NOAC's dosing …

Background To assess long-term effectiveness and safety of edoxaban in Europe. Methods
and results ETNA-AF-Europe, a prospective, multinational, multi-centre, post-authorisation …

Background Treatment with intravenous thrombolysis for acute ischemic stroke is
contraindicated with intake of apixaban/rivaroxaban in the last 48 hours. Recent European …

Non-vitamin K antagonist oral anticoagulants (NOACs) are a new class of anticoagulant
drugs used in the prevention and treatment of venous thromboembolism (VTE) and atrial …

In a systemic review of randomized controlled trials and cohort studies on oral
anticoagulation in atrial fibrillation (AF) patients published by Li et al 1 in the latest issue of …

In the latest issue of The Anatolian Journal of Cardiology, I have read with keen interest the
article by Güzel et al 1 showing the current anticoagulation practice among atrial fibrillation …

The choice of an OAC (oral anticoagulant) for patients with non-valvular atrial fibrillation
(NVAF) is a very complex process. For many years the gold standard in the treatment of …